“
TL;DR
Treatment with XEN1101, especially the 25 mg dose, was associated with a significant, dose-dependent reduction in monthly seizure frequency compared to placebo.
JAMA Neurology · 12 authors, 7 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
Treatment with XEN1101, especially the 25 mg dose, was associated with a significant, dose-dependent reduction in monthly seizure frequency compared to placebo.
The primary efficacy analysis showed a statistically significant and dose-dependent reduction in monthly focal-onset seizure frequency for all XEN1101 doses compared to placebo. XEN1101 was generally well tolerated, with dizziness, somnolence, and fatigue as the most common adverse events. The serious adverse event incidence was low and balanced across groups. Limitations include the relatively short 8-week treatment duration and smaller sample sizes in the 10 mg and 20 mg dose groups. The study was conducted in a highly treatment-resistant population.